Crit Care Med:维生素C对重症患者临床疗效的影响

2019-03-05 xing.T 网络

由此可见,在ICU患者的混合人群中,维生素C给药对患者生存、ICU住院长短或住院时间没有显著影响。在心脏手术中,对术后心房颤动、ICU或住院时间的有益影响仍不清楚。然而,证据的质量和数量仍不足以得出确切的结论,该分析既不支持也不阻止这些人群使用维生素C。

维生素C给药对危重病人临床结局的影响仍存在争议。近日,危重病医学领域权威杂志Critical Care Medicine上针对这一问题发表了一篇系统评价文章。

研究人员检索了在线数据库,检索时间截止至2018年10月1日,选择了在成人危重病患者中使用维生素C(任何治疗方案)与安慰剂或不治疗对比的随机对照试验。研究人员使用随机效应模型荟萃分析计算二分类结果的风险比和95%CI的连续结果的标准化平均差异。

研究人员共分析了44个随机研究,其中16个在ICU中进行(2857例患者),28个在心脏手术患者中进行(3598例患者),这些研究发表于1995年和2018年之间。在ICU患者中,与对照组相比,维生素C给药与死亡率(风险比为0.90; 95%CI为0.74-1.10; p=0.31)、急性肾损伤、ICU或住院时间长短的差异无关。在心脏手术患者中,维生素C与术后心房颤动(风险比为0.64; 95%CI为0.52-0.78; p<0.0001)、ICU停留时间(标准化平均差异为-0.28天; 95%CI为-0.43至-0.13天; p=0.0003)和住院时间(标准化平均差异为-0.30天; 95%CI为-0.49至-0.10天; p=0.002)减少有关。此外,未发现术后死亡率、急性肾损伤、卒中和室性心律失常的组间差异。

由此可见,在ICU患者的混合人群中,维生素C给药对患者生存、ICU住院长短或住院时间没有显著影响。在心脏手术中,对术后心房颤动、ICU或住院时间的有益影响仍不清楚。然而,证据的质量和数量仍不足以得出确切的结论,该分析既不支持也不阻止这些人群使用维生素C。

原始出处:


Putzu, Alessandro.et al.The Effect of Vitamin C on Clinical Outcome in Critically Ill Patients A Systematic Review With Meta-Analysis of Randomized Controlled Trials.critical care medicine.2019. https://journals.lww.com/ccmjournal/Abstract/onlinefirst/The_Effect_of_Vitamin_C_on_Clinical_Outcome_in.96009.aspx

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1907188, encodeId=39f0190e18816, content=<a href='/topic/show?id=acc02289e40' target=_blank style='color:#2F92EE;'>#临床疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22897, encryptionId=acc02289e40, topicName=临床疗效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sun Dec 01 06:50:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365747, encodeId=559b365e4795, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun May 05 09:27:29 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284056, encodeId=df5c12840560c, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Thu Mar 07 11:50:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609623, encodeId=e89a16096238b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 07 11:50:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032087, encodeId=7850103208ead, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Mar 05 23:50:00 CST 2019, time=2019-03-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1907188, encodeId=39f0190e18816, content=<a href='/topic/show?id=acc02289e40' target=_blank style='color:#2F92EE;'>#临床疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22897, encryptionId=acc02289e40, topicName=临床疗效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sun Dec 01 06:50:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365747, encodeId=559b365e4795, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun May 05 09:27:29 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284056, encodeId=df5c12840560c, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Thu Mar 07 11:50:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609623, encodeId=e89a16096238b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 07 11:50:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032087, encodeId=7850103208ead, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Mar 05 23:50:00 CST 2019, time=2019-03-05, status=1, ipAttribution=)]
    2019-05-05 一天没事干

    很好的学习机会

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1907188, encodeId=39f0190e18816, content=<a href='/topic/show?id=acc02289e40' target=_blank style='color:#2F92EE;'>#临床疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22897, encryptionId=acc02289e40, topicName=临床疗效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sun Dec 01 06:50:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365747, encodeId=559b365e4795, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun May 05 09:27:29 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284056, encodeId=df5c12840560c, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Thu Mar 07 11:50:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609623, encodeId=e89a16096238b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 07 11:50:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032087, encodeId=7850103208ead, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Mar 05 23:50:00 CST 2019, time=2019-03-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1907188, encodeId=39f0190e18816, content=<a href='/topic/show?id=acc02289e40' target=_blank style='color:#2F92EE;'>#临床疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22897, encryptionId=acc02289e40, topicName=临床疗效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sun Dec 01 06:50:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365747, encodeId=559b365e4795, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun May 05 09:27:29 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284056, encodeId=df5c12840560c, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Thu Mar 07 11:50:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609623, encodeId=e89a16096238b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 07 11:50:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032087, encodeId=7850103208ead, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Mar 05 23:50:00 CST 2019, time=2019-03-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1907188, encodeId=39f0190e18816, content=<a href='/topic/show?id=acc02289e40' target=_blank style='color:#2F92EE;'>#临床疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22897, encryptionId=acc02289e40, topicName=临床疗效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8346212, createdName=respect, createdTime=Sun Dec 01 06:50:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365747, encodeId=559b365e4795, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Sun May 05 09:27:29 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284056, encodeId=df5c12840560c, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Thu Mar 07 11:50:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609623, encodeId=e89a16096238b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 07 11:50:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032087, encodeId=7850103208ead, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Mar 05 23:50:00 CST 2019, time=2019-03-05, status=1, ipAttribution=)]
    2019-03-05 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

Front Physiol:维生素C摄入和前列腺癌风险研究

维生素C是一种还原物质和自由基清除物质,在细胞内的质膜上具有抗氧化作用。基于这些特性,相关研究人员调查了维生素C在癌症发生率上的影响。但是基于大群体的与前列腺癌相关的研究很少,并且证据显示倾向于认为维生素C与前列腺癌没有相关性。尽管如此,许多之前的研究忽视了前列腺癌的恶化,以及筛选和组织检测,这也导致了倾向性相关性的存在。最近,有研究人员在加拿大蒙特利尔进行了基于大群体的研究。研究发现,日常摄入维

Asian Pac J Allergy Immunol:有氧训练和维生素C补充对过敏性鼻炎患者鼻炎症状的影响研究

运动锻炼和维生素C补充在许多疾病的症状治疗中均推荐作为一种有效的辅助治疗方法。然而,它们对鼻炎症状的影响仍旧不清楚。最近,有研究人员评估了单独的有氧训练和有氧训练结合维生素C补充对分别对过敏性鼻炎患者症状的影响。研究包括了27名鼻炎患者,并被随机分配到3个小组:对照组(CON;n=8),训练组(EX;n=9)和锻炼与维生素C结合组(EX+Vit.C;n=10)。锻炼的方法包括走路和或者跑步。维生素

摄入维生素C或其它补充剂真能有效减缓感冒的症状吗?

当你感冒时,或许会想到市面上很多维生素和补品,它们能够有效缓解感冒症状,帮助机体更快地恢复,减少感冒的几率;说道普通感冒(也被称为上呼吸道感染),似乎并没有什么灵丹妙药,但一些补充剂似乎只能带来很小的改善。以下是一些最新的研究结果。

这28种药,不宜与维C联用!

维生素C在临床中主要用于维生素C缺乏病的治疗以及维生素C的补充治疗,有针剂与口服制剂两种剂型,在临床应用中多采用与其他药物联用的方式起到治疗效果,因此就不得不注意维生素C与药物间的联用情况。

维生素C对尿干化学究竟有哪些影响?这篇文章说的最透彻!

随着科技进步,尿液干化学法因操作简便、快速、自动化程度高,广泛应用于临床。但干化学法在检测原理有一定的局限性,而且容易受物理、化学、药物等因素干扰。众所周知,维生素C是一种价廉、毒副作用较少的药物,该药在临床上的应用日趋广泛,与多种疾病的防治关系密切。临床上常用于肝炎、肝硬化、化学毒物中毒、各种贫血、过敏性疾病、紫癜及各种急性和慢性传染病的辅助治疗,也可用于预防和治疗动脉粥样硬化和肿瘤等,因为维生

维生素C:危重症患者应该补充吗?

我们中的许多人会将维生素C缺乏与在“探索时代”中死于坏血病的水手联系起来。然而,现在已经很明显,维生素C缺乏肯定不是过去的事情,而是在极端情况下发展而来。